Diacetylmorphine versus methadone for the treatment of opioid addiction.
about
Heroin maintenance for chronic heroin-dependent individualsHeroin maintenance for chronic heroin-dependent individualsOpioid substitution and antagonist therapy trials exclude the common addiction patient: a systematic review and analysis of eligibility criteriaImpact of Chronic Pain on Treatment Prognosis for Patients with Opioid Use Disorder: A Systematic Review and Meta-analysisCost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug usersEffects of cortisol administration on craving in heroin addictsEvaluation of a low-threshold/high-tolerance methadone maintenance treatment clinic in saint john, new brunswick, Canada: one year retention rate and illicit drug usePharmacological maintenance treatments of opiate addiction.Income level and drug related harm among people who use injection drugs in a Canadian settingMen's and women's response to treatment and perceptions of outcomes in a randomized controlled trial of injectable opioid assisted treatment for severe opioid use disorder.Impact of lifetime opioid exposure on arterial stiffness and vascular age: cross-sectional and longitudinal studies in men and women.Differential long-term outcomes for voluntary and involuntary transition from injection to oral opioid maintenance treatmentThe World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence.Client satisfaction among participants in a randomized trial comparing oral methadone and injectable diacetylmorphine for long-term opioid-dependency.Heroin maintenance treatment: from idea to research to practice.Deep brain stimulation compared with methadone maintenance for the treatment of heroin dependence: a threshold and cost-effectiveness analysis.The effectiveness of opioid substitution treatments for patients with opioid dependence: a systematic review and multiple treatment comparison protocol.A chance to stop and breathe: participants' experiences in the North American Opiate Medication Initiative clinical trialBAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP.Normalizing effect of heroin maintenance treatment on stress-induced brain connectivity.Increased functional connectivity in the resting-state basal ganglia network after acute heroin substitution.Sex work involvement among women with long-term opioid injection drug dependence who enter opioid agonist treatment.Understanding Heroin Overdose: A Study of the Acute Respiratory Depressant Effects of Injected Pharmaceutical Heroin.Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment.Improving community health and safety in Canada through evidence-based policies on illegal drugs.An Engineered Endomorphin-2 Gene for Morphine Withdrawal SyndromeFactors associated with willingness to participate in a pharmacologic addiction treatment clinical trial among people who use drugsSustained release oral morphine as an alternative to methadone for the treatment of opioid-use disorder post Torsades de Pointes cardiac arrestThe street cost of drugs and drug use patterns: relationships with sex work income in an urban Canadian settingResponse inhibition and psychomotor speed during methadone maintenance: impact of treatment duration, dose, and sleep deprivation.The effect of prescription opioid injection on the risk of non-fatal overdose among people who inject drugs.Contribution of BDNF and DRD2 genetic polymorphisms to continued opioid use in patients receiving methadone treatment for opioid use disorder: an observational study.An Ethical Exploration of Barriers to Research on Controlled Drugs.HIV infection among people who inject drugs: the challenge of racial/ethnic disparities.Seeking prescription opioids from physicians for nonmedical use among people who inject drugs in a Canadian setting.Opiate dependence as an independent and interactive risk factor for arterial stiffness and cardiovascular ageing - a longitudinal study in femalesRemission of Severe Opioid Use Disorder with Ibogaine: A Case Report.Lifetime opiate exposure as an independent and interactive cardiovascular risk factor in males: a cross-sectional clinical study.Efficacy of prescribed injectable diacetylmorphine in the Andalusian trial: Bayesian analysis of responders and non-responders according to a multi domain outcome index.Scientific and political challenges in North America's first randomized controlled trial of heroin-assisted treatment for severe heroin addiction: rationale and design of the NAOMI study.
P2860
Q24234080-DDD04A5C-4A99-4CE3-B259-13303814E1C2Q24236411-280A4C94-B0FD-429B-AB86-120F90CE63EEQ26778626-B6A8846C-CE28-453B-A2A6-963EDA396316Q26785010-D3467512-B209-4F4E-A069-D0D637EB26D8Q28483820-A0BA99CC-D9FF-4B62-BB91-B262700052BAQ29396174-3C4F4B32-984E-45C8-A6F4-7B5C20926512Q33560231-698D234F-84A3-4096-B8D3-23CA19FDD1C5Q33582080-14D9CA33-E6A0-4B5D-AF83-4960DD551B89Q33693401-8DC9DA8A-305F-46A2-B2B3-02DEAFA53F12Q33706783-2E1C7AC0-FD66-405B-99B5-4FB7C5A102F2Q33744915-4DE920BA-65CC-4D81-A0C1-1DDF56FA072EQ33781890-DA9D79E2-4967-48D8-9E61-7FB291206C5BQ33870389-F9C74B9C-A479-43FB-A5CF-D3C64B88E87AQ33972137-D9B06C9C-3AB6-44E0-83E9-F0CC4D9B40FBQ34168596-E636279A-1E58-4084-99DD-E5475CD117BEQ34216585-CBC4C505-F807-4DD5-8D1A-15BFE5D79345Q34226309-29059D68-6EB3-435A-BBD0-8B978DA17C5CQ34274002-11F371CC-4071-428A-87C4-5120821434D5Q34277168-372570F2-33A5-45F7-A97C-75C39E5FEB91Q34842349-48000617-DEC9-440C-86E8-A3E3C11A3A63Q35161423-B13CDE95-DADD-4188-8AE5-8554A762C5A1Q35763461-1C72FBAC-CBBD-41DE-8030-4285E64E6DF6Q35818546-32EBBD2B-5B86-4749-A0EB-EDF57F180C55Q35856799-A7D044F5-C13B-4C2F-B17C-82380DA124BBQ35896342-9060F832-E729-45D2-A814-4EE2433DFE66Q35966106-34308FBD-A461-4A23-96EA-B8AAAC7A74FBQ36079296-29EEE9C3-FDD8-4252-ACBF-B7B58C8FFAFBQ36080474-5C5A0ABB-5DEA-4DFD-BD11-4B66D1CD67BAQ36083418-44AD1549-A511-4350-976A-F6A2015418F6Q36164768-E48A2552-6FFE-421F-942B-66C07ECAD328Q36248958-D781982C-8B93-48E6-AA74-4795D22D2DA8Q36354160-64E7C873-E807-44D0-B759-96CB80B9090FQ36847484-BFBA0A6C-C993-48F6-9B2F-8DE689E9F11FQ37009231-FFB18791-2E67-4ABD-AECE-1CB6AF0E975AQ37097438-C45D9D39-1798-4AE4-B260-5D02EA5CC12CQ37108575-60BDCB7C-BC84-4537-BDA5-A96DD5FEC357Q37193780-43DB947D-5B0D-40F3-91E8-DEFB5C28A97AQ37225383-ACFEDF6C-F1AA-4996-87D7-51611A2ACA4AQ37336855-3EC0938E-EBBC-49CC-8B7A-3BC64A0BD51AQ37452336-AB1260BC-A3D2-4893-9571-3FABF6082CA5
P2860
Diacetylmorphine versus methadone for the treatment of opioid addiction.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Diacetylmorphine versus methadone for the treatment of opioid addiction.
@en
Diacetylmorphine versus methadone for the treatment of opioid addiction.
@nl
type
label
Diacetylmorphine versus methadone for the treatment of opioid addiction.
@en
Diacetylmorphine versus methadone for the treatment of opioid addiction.
@nl
prefLabel
Diacetylmorphine versus methadone for the treatment of opioid addiction.
@en
Diacetylmorphine versus methadone for the treatment of opioid addiction.
@nl
P2093
P2860
P50
P356
P1476
Diacetylmorphine versus methadone for the treatment of opioid addiction.
@en
P2093
Aslam Anis
Daphne Guh
Eugenia Oviedo-Joekes
Pierre Lauzon
P2860
P304
P356
10.1056/NEJMOA0810635
P407
P577
2009-08-01T00:00:00Z